For example, while not needed to make a clinical diagnosis of SCI (Jessen et al., 2014), AD-related biological indicators (e.g. CSF biomarkers and amyloid and tau PET imaging) might provide valuable information on how processing uncertainty and information gathering relates to AD pathology in preclinical population with SCI. This evidence concerns the gene MAPT and Alzheimer disease.